{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:43:04Z","timestamp":1777160584157,"version":"3.51.4"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hologic Inc"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,2,18]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To estimate the impact of using the Aptima messenger RNA (mRNA) high-risk human papilloma virus (HR-HPV) assay versus a DNA HR-HPV assay in a primary HPV cervical screening programme.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>One hypothetical cohort followed for 3\u2009years through HPV primary cervical screening.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>A hypothetical cohort of women aged 25\u201365 years tested in the National Health Service (NHS) Cervical Screening Programme (CSP) for first call or routine recall testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A decision tree parameterised with data from the CSP (2017\/18) and the HORIZON study. Uncertainty analyses were conducted using data from the FOCAL and GAST studies, other DNA HPV tests in addition to one-way and probabilistic sensitivity and scenarios analyses, to test the robustness of results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Aptima mRNA HR-HPV assay and a DNA HR-HPV assay (cobas 4800 HPV assay).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Primary: total colposcopies and total costs for the cohort. Secondary: total HPV and cytology tests, number lost to follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline for a population of 2.25\u2009million women, an estimated \u00a315.4\u2009million (95%\u2009credibility intervals (CI) \u00a36.5 to 24.1\u2009million) could be saved and 28\u2009009 (95% CI 27\u2009499 to 28 527) unnecessary colposcopies averted if Aptima mRNA assays are used instead of a DNA assay, with 90\u2009605 fewer unnecessary HR-HPV and 253\u2009477 cytology tests performed. These savings are due to a lower number of HPV positive samples in the mRNA arm. When data from other primary HPV screening trials were compared, results indicated that using the Aptima mRNA assay generated cost savings and reduced testing in every scenario.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Using the Aptima mRNA assay versus a DNA assay would almost certainly yield cost savings and reduce unnecessary testing and procedures, benefiting the NHS and women in the CSP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-031303","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T05:39:29Z","timestamp":1583732369000},"page":"e031303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-7150","authenticated-orcid":false,"given":"Georgie","family":"Weston","sequence":"first","affiliation":[{"name":"Aquarius Population Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dombrowski","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Harvey","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Iftner","sequence":"additional","affiliation":[{"name":"Department of Medical Virology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kyrgiou","sequence":"additional","affiliation":[{"name":"Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Imperial College London, London, UK"},{"name":"Queen Charlotte\u2019s and Chelsea, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Founta","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Musgrove Park Hospital, Taunton & Somerset NHS Foundation Trust, Taunton, Somerset, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth J","family":"Adams","sequence":"additional","affiliation":[{"name":"Aquarius Population Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,3,8]]},"reference":[{"key":"2025101810103157000_10.3.e031303.1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.bjc.6602069","article-title":"Cervical cancer screening programmes and policies in 18 European countries","volume":"91","author":"Anttila","year":"2004","journal-title":"Br J Cancer"},{"key":"2025101810103157000_10.3.e031303.2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4424"},{"key":"2025101810103157000_10.3.e031303.3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ijc.29719","article-title":"Factors associated with type-specific persistence of high-risk human papillomavirus infection: a population-based study","volume":"138","author":"Stensen","year":"2016","journal-title":"Int J Cancer"},{"key":"2025101810103157000_10.3.e031303.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"2025101810103157000_10.3.e031303.5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2018.09.004","article-title":"Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV focal trial","volume":"108","author":"Cook","year":"2018","journal-title":"J Clin Virol"},{"key":"2025101810103157000_10.3.e031303.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.12.003"},{"key":"2025101810103157000_10.3.e031303.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27636"},{"key":"2025101810103157000_10.3.e031303.8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24010"},{"key":"2025101810103157000_10.3.e031303.9","doi-asserted-by":"crossref","unstructured":"Saville M , Sultana F , Malloy MJ , et al . Clinical validation of the COBAS HPV test on the COBAS 6800 system for the purpose of cervical screening. J Clin Microbiol 2019;57. doi:doi:10.1128\/JCM.01239-18","DOI":"10.1128\/JCM.01239-18"},{"key":"2025101810103157000_10.3.e031303.10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01517-13"},{"key":"2025101810103157000_10.3.e031303.11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ijc.31819","article-title":"HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri","volume":"144","author":"Forslund","year":"2019","journal-title":"Int J Cancer"},{"key":"2025101810103157000_10.3.e031303.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.095"},{"key":"2025101810103157000_10.3.e031303.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.22"},{"key":"2025101810103157000_10.3.e031303.14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2016.12.004","article-title":"Aptima HPV Assay versus Hybrid Capture\u00ae 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial","volume":"87","author":"Cook","year":"2017","journal-title":"J Clin Virol"},{"key":"2025101810103157000_10.3.e031303.15","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01013-15"},{"key":"2025101810103157000_10.3.e031303.16","doi-asserted-by":"crossref","unstructured":"Iftner T , Neis K-J , Castanon A , et al . Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol 2019;57. doi:doi:10.1128\/JCM.01177-18","DOI":"10.1128\/JCM.01177-18"},{"key":"2025101810103157000_10.3.e031303.17","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPHVD7MIP3FYVV"},{"key":"2025101810103157000_10.3.e031303.18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25726"},{"key":"2025101810103157000_10.3.e031303.19","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jcv.2015.10.027","article-title":"A review of the clinical performance of the Aptima HPV assay","volume":"76","author":"Haedicke","year":"2016","journal-title":"J Clin Virol"},{"key":"2025101810103157000_10.3.e031303.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l240"},{"key":"2025101810103157000_10.3.e031303.21","unstructured":"Public Health England, NHS Screening programmes . HPV primary screening pilot protocol algorithm, 2016. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/529496\/HPVPSFlowchart-Version3_Jan16.CURRENTppt.pdf"},{"key":"2025101810103157000_10.3.e031303.22","unstructured":"Pathway Analytics . Smear Test [Internet]. Available: https:\/\/www.pathwayanalytics.com\/pathways\/19-srh-standard\/113-smear-test [Accessed 30 Nov 2018]."},{"key":"2025101810103157000_10.3.e031303.23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41416-019-0547-x","article-title":"16\/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot","volume":"121","author":"Rebolj","year":"2019","journal-title":"Br J Cancer"},{"key":"2025101810103157000_10.3.e031303.24","unstructured":"NHS Digital . Cervical Screening Programme, England - 2017-2018, 2018. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cervical-screening-programme\/england-2017-2018"},{"key":"2025101810103157000_10.3.e031303.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-019-0743-0","article-title":"HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the COBAS 6800 in comparison to the 4800 system","volume":"19","author":"Frayle","year":"2019","journal-title":"BMC Womens Health"},{"key":"2025101810103157000_10.3.e031303.26","unstructured":"Arbyn M . International Agency for Research on Cancer, editors. In: European guidelines for quality assurance in cervical cancer screening (Europe against cancer). 2nd edn. Luxembourg: Office for Official Publ. on the Europ. Communities, 2008: 291."},{"key":"2025101810103157000_10.3.e031303.27","unstructured":"Curtis LA , Burns A . Unit Costs of Health and Social Care 2017 [Internet]. S.l: Personal Social Services Research Unit, University of Kent, 2017. Available: https:\/\/doi.org\/10.22024\/UniKent\/01.02\/65559 <https:\/\/doi.org\/10.22024\/UniKent\/01.02\/65559"},{"key":"2025101810103157000_10.3.e031303.28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1471-0528.2007.01261.x","article-title":"Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales","volume":"114","author":"Martin-Hirsch","year":"2007","journal-title":"BJOG: An International Journal of Obstetrics Gynaecology"},{"key":"2025101810103157000_10.3.e031303.29","unstructured":"NHS England and NHS Improvement . 2017\/18 and 2018\/19 national tariff payment system, 2017. Available: https:\/\/improvement.nhs.uk\/resources\/national-tariff-1719\/"},{"key":"2025101810103157000_10.3.e031303.30","unstructured":"NICE . The guidelines manual, guidance and guidelines. Available: https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness [Accessed 30 Nov 2018]."},{"key":"2025101810103157000_10.3.e031303.31","unstructured":"CERVIVA . Promoting quality research in HPV associated diseases. Available: http:\/\/cerviva.ie\/ [Accessed 18 Dec 2018]."},{"key":"2025101810103157000_10.3.e031303.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.04.012"},{"key":"2025101810103157000_10.3.e031303.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147326","article-title":"Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above","volume":"11","author":"Rebolj","year":"2016","journal-title":"PLoS One"},{"key":"2025101810103157000_10.3.e031303.34","doi-asserted-by":"publisher","DOI":"10.3310\/hta13320"},{"key":"2025101810103157000_10.3.e031303.35","unstructured":"GENOMICA S.A.U . In vitro diagnostics - Products - CLART\u00ae HPV. Available: http:\/\/genomica.es\/en\/in_vitro_diagnostics_products_clart_hpv2.cfm [Accessed 3 Jan 2019]."},{"key":"2025101810103157000_10.3.e031303.36","unstructured":"GOV.UK . Cervical screening: acceptable HPV tests. Available: https:\/\/www.gov.uk\/government\/publications\/cervical-screening-acceptable-hpv-tests\/cervical-screening-acceptable-hpv-tests [Accessed 4 Nov 2019]."},{"key":"2025101810103157000_10.3.e031303.37","unstructured":"GOV.UK . Cervical screening: Approved HPV tests for HPV triage and test of cure. Available: https:\/\/www.gov.uk\/guidance\/cervical-screening-approved-hpv-tests-for-hpv-triage-and-test-of-cure [Accessed 2 Jan 2019]."},{"key":"2025101810103157000_10.3.e031303.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2569","article-title":"Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study","volume":"339","author":"Castle","year":"2009","journal-title":"BMJ"},{"key":"2025101810103157000_10.3.e031303.39","doi-asserted-by":"publisher","DOI":"10.1086\/516784"},{"key":"2025101810103157000_10.3.e031303.40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn044"},{"key":"2025101810103157000_10.3.e031303.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(09)70009-5"},{"key":"2025101810103157000_10.3.e031303.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.06.015"},{"key":"2025101810103157000_10.3.e031303.43","unstructured":"Department of Health . Cervical screening: programme overview. Available: https:\/\/www.gov.uk\/guidance\/cervical-screening-programme-overview [Accessed 24 Oct 2018]."},{"key":"2025101810103157000_10.3.e031303.44","unstructured":"Cameron RL , Pollock KG . The impact of the human papillomavirus vaccine in Scotland: a changing landscape. Pharmaceutical Journal 2017;9."},{"key":"2025101810103157000_10.3.e031303.45","unstructured":"Shearer B . HPV vaccination: understanding the impact on HPV disease. Canadian Network on HPV prevention; 2011. Report no: 34, 2019."},{"key":"2025101810103157000_10.3.e031303.46","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354"},{"key":"2025101810103157000_10.3.e031303.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.125"},{"key":"2025101810103157000_10.3.e031303.48","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2006.023333"},{"key":"2025101810103157000_10.3.e031303.49","unstructured":"Moss S , Gray A , Marteau T , et al . Evaluation of HPV\/LBC cervical screening pilot studies report to the Department of health, 2004. Available: http:\/\/www.cancerscreening.nhs.uk\/cervical\/evaluation-hpv-2006feb.pdf"},{"key":"2025101810103157000_10.3.e031303.50","doi-asserted-by":"publisher","DOI":"10.3310\/hta18520"},{"key":"2025101810103157000_10.3.e031303.51","unstructured":"Pathway Analytics . Sexual health tariff, 2013. Available: http:\/\/www.pathwayanalytics.com\/cms\/sh-tariff"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-031303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:10:43Z","timestamp":1760807443000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-031303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,8]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjopen-2019-031303"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-031303","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}